Table 7.
Trials using anti-EGFR MAbs with other targeted therapies in chemotherapy-resistant mCRC in KRAS WT patients.
| Trial (author) | Phase | Protocol | Number enrolled | Results |
HR (95% CI) | P value | |
|---|---|---|---|---|---|---|---|
| PFS | OS | ||||||
| AGITG CO.20 (Siu et al.) [31] |
III | Cetuximab + brivanib alaninate cetuximab |
376 374 |
5.0 mos. 3.4 mos. |
8.8 mos. 8.1 mos. |
PFS: 0.72 (0.62–0.84) OS: 0.88 (0.74–1.03) |
<0.0001 0.12 |
|
| |||||||
| — (Watkins et al.) [32] | II/III | Dalotuzumab 10 mg/kg 1 week + cetuximab + irinotecan versus |
Total enrolled 345 WT | 3.3 mos. | 10.8 mos. |
PFS: NR OS: NR |
|
| dalotuzumab 7.5 mg/kg q 2 weeks versus |
5.4 mos. | 11.6 mos. | |||||
| placebo + cetuximab + irinotecan | 5.6 mos. | 14.0 mos. | |||||
WT: wild type, PFS: progression free survival, OS: overall survival, NR: not reported.